Dennis Chen

Corporate Officer/Principal at PROMIS NEUROSCIENCES, INC.

Health Technology

Profile

Dennis Chen is currently the Head of Manufacturing at ProMIS Neurosciences, Inc. He previously worked as the Director of Process Development & Manufacturing at Geron Corp.
and as the Director of CMC Regulatory Affairs at Intarcia Therapeutics, Inc.

Dennis Chen active positions

Companies	Position	Start
PROMIS NEUROSCIENCES, INC.	Corporate Officer/Principal	-

All active positions of Dennis Chen

Former positions of Dennis Chen

Companies	Position	End
GERON CORPORATION	Corporate Officer/Principal	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Corporate Officer/Principal	-

See the detail of Dennis Chen's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dennis Chen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
GERON CORPORATION	Health Technology
PROMIS NEUROSCIENCES, INC.	Health Technology

Private companies	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology